SAB Biotherapeutics Inc Cash Flow Conversion Efficiency
SAB Biotherapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, SAB Biotherapeutics Inc (SABS) has a cash flow conversion efficiency ratio of -0.112x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-24.11 Million) by net assets ($214.78 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of SAB Biotherapeutics Inc (2019–2025)
Cash flow conversion efficiency of SAB Biotherapeutics Inc from 2019 to 2025. This chart illustrates how SAB Biotherapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View SAB Biotherapeutics Inc (SABS) stock price for real-time trading data and today's change.
SAB Biotherapeutics Inc Cash Flow Conversion Ratio Explained
SAB Biotherapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
SAB Biotherapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SAB Biotherapeutics Inc ranked by their cash flow conversion efficiency. Also see SAB Biotherapeutics Inc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Great Tree Pharmacy Co Ltd
TWO:6469
|
0.120x |
|
i3system Inc
KQ:214430
|
0.073x |
|
Armada Acquisition Corp. II
NASDAQ:XRPN
|
0.002x |
|
Alico Inc
NASDAQ:ALCO
|
-0.052x |
|
Médica Sur S.A.B. de C.V
MX:MEDICAB
|
-0.033x |
|
Hospital Mater Dei S.A
SA:MATD3
|
0.057x |
|
First Northern Community Bancorp Common stock
NASDAQ:FNRN
|
0.016x |
|
Braskem S.A.
SA:BRKM3
|
0.215x |
Annual Cash Flow Conversion Efficiency for SAB Biotherapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of SAB Biotherapeutics Inc from 2019 to 2025. Review how much free cash does SAB Biotherapeutics Inc generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $151.49 Million | $-44.78 Million | -0.296x | +77.62% |
| 2024-12-31 | $25.97 Million | $-34.29 Million | -1.320x | -201.21% |
| 2023-12-31 | $57.30 Million | $-25.12 Million | -0.438x | +41.96% |
| 2022-12-31 | $31.06 Million | $-23.46 Million | -0.755x | -1565.54% |
| 2021-12-31 | $38.55 Million | $1.99 Million | 0.052x | -79.90% |
| 2020-12-31 | $39.01 Million | $10.00 Million | 0.256x | -93.58% |
| 2019-12-31 | $-2.31 Million | $-9.21 Million | 3.997x | -- |
About SAB Biotherapeutics Inc
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes … Read more